VistaCare Medical

Clinical evidence


Our post-marketing clinical study has allowed us to provide clinical monitoring of our VistaCare One medical device after obtaining the CE Mark.

The subject of the study was the open-label evaluation of the effects of VistaCare® treatment in routine practice in patients with acute and chronic leg wounds. Initially, it was a question of evaluating the performance and safety of use of the VistaCare device. Secondly  it was necessary to determine the deadline for quality bud and collect reported adverse events.

The study was prospective, open-label, and multicenter; it was carried out within four CHU departments, with different specialties, and was coordinated by Professor Dominique Casanova.

The follow-up of the study, the statistical analyzes and the final evaluations of the blind images at the end of the study were carried out by organizations and an independent doctor.

Point number 1

31 patients had given their consent to enter the study, 5 patients left the study, including 1 patient who was not included because he did not meet the inclusion/exclusion criteria and 4 exits were premature, which gives us a “Per Protocol” population of 26 patients, who were followed up to obtain granulation tissue and its follow-up up to D+30.

Point number 2

A large majority of wounds were chronic, almost half of them were more than a year old, also more than 15% were more than 5 years old. 93% of the wounds were judged as difficult, most of them failing with conventional treatments.

Point number 3

The majority of wounds were ≥ 10m2 and had defects.


Key figures

0123456789001234567890                     ,01234567890

± 3,9 jours*: time to obtain optimum granulation tissue to decide of a covering gesture (graft, dressing, flap) ~ 3 to 4 hours of daily interruption

* To compare ATEC study: Algosteril®: 19.98 days and TPN: 20.56 days

Acute Wound Cohort.

0123456789001234567890                     h

the level of pain falls drastically

0123456789001234567890                     ,01234567890

%: improvement after a 7-day treatment only under VistaCare® including 14 patients at +1 year of treatment.

0123456789001234567890                     ,01234567890

improvement at a distance (23 patients) from the treatment (at 30 days). For the other three: 2 failures not attributed to VistaCare and 1 static state.
**Transplant performed and 1 patient improving at the end of VistaCare® treatment.


REAL LIFE DATAClinical cases

The effectiveness of VistaCare in everyday practice

The collection of clinical cases allows the evaluation of the therapeutic effects of one or more treatments “in real life”, whether this result is positive or even negative. This is why we have collected several clinical cases to monitor the effectiveness of WEC therapy in the treatment of complex wounds.

All the clinical cases collected reinforce the results of the clinical study which reports the obtaining of quality granulation tissue in 10 days, more or less 4 days.

We will also note 88.5% improvement in wounds at a distance from treatment (i.e. at 30 days) with complete healing at around 40 days. The collection of clinical cases also makes it possible to retrieve more precise data on the type of acute and chronic wounds processed by VistaCare.


Different chronic clinical cases

VistaCare is now deployed in around thirty healthcare establishments in France and treats so-called chronic wounds on a daily basis. Below we bring you different examples of clinical cases treated with our device.

Different acute clinical cases

VistaCare supports so-called acute wounds as well as chronic wounds. We therefore also present below various examples of clinical cases treated with our device.

Scientific Literature

Abstract clinical study OPEN PMCF VistaCare Medical:

By following this link you will find the details of the clinical study results. OPEN PMCF performed after obtaining the CE marking for our VistaCare One device.

If you wish to obtain the clinical study abstract, please contact us at and we will get back to you quickly.

Scientific Posters :

These scientific posters were produced by clinicians who use our VistaCare One device, they illustrate and confirm the results of our clinical study in real life.

FAQsFrequently Asked Questions

  • Question 1
  • Question 2
  • Question 3

Is VistaCare therapy continuous?

The patient must keep the leg/lower limb in the chamber for a maximum of time during the day (almost continuously). Nevertheless, we recommend taking breaks twice a day (approximately 2-3 hours of treatment interruption in the morning and afternoon), to allow the patient to carry out his daily care but also to be able to move walk or sit in a chair, in order to avoid the loss of autonomy and above all the appearance of bedsores.

For us this wandering is one of the elements of treatment in order to fight against decubitus problems in general.
In addition, this verticalization will simplify debridement for the nurse, who can do it easily in the patient’s bed or only in the shower. This simple debridement is one of the advantages of the technique.

Can the treatment be done at home/HAD?

The VistaCare One product has been designed for use in hospital structures/departments and care facilities only. Currently, it cannot be used in patients’ homes. However, this product is destined to evolve, a device for home use is under development.

What are the indications (type of wounds) eligible for WEC therapy?

The VistaCare has been designed for the management of complex wounds, whether they are considered acute or chronic wounds. We collected several clinical cases of wounds having benefited from WEC therapy.
Acute wounds: burns, traumatic wounds, degloving, wounds with severe loss of substance.
Chronic wounds: venous, arterial, mixed ulcers, necrotizing angiodermatitis or sluggish wounds that have not evolved for several months or several years.
Ce site est réservé aux professionnels de santé.

Êtes-vous un professionnel de santé ?

The site is reserved for healthcare professionals.

Are you a healthcare professional ?